In contrast, HB-EGF protects against phenotypes related to metabolic syndrome and advanced metabolic disorders, suggesting that HB-EGF is a potential target against metabolic diseases, such as hyperinsulinemia, hyperglycemia, and increased oxidative stress, all of which are in common with insulin dysregulation [18]. This evidence concerns the gene INS and metabolic disease.